• Ticker

DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$4.15 -$0.05 (-1.19%)

REAL-TIME: Last trade at

Targacept , Inc.

NASDAQ:TRGT

Promising USF drug falls short in trials

Targacept (TRGT) Estimates Lifted By Oppenheimer After Q1, 'Perform' Maintained

Targacept Reports First Quarter 2012 Financial Results

Targacept posts smaller Q1 profit

Targacept reports Q1 EPS 7c, may not compare to consensus (25c)

Company news: Biogen Idec and Targacept

Targacept, Inc., AstraZeneca PLC End Partnership on Failed Drug

AstraZeneca officially terminates TC-5214 licensing agreement with Targacept

Targacept received notice of termination of collaboration with AstraZeneca

Targacept falls 5.4%

CEO of Targacept partner AstraZeneca resigns

Targacept laying off 65 people

Targacept To Lay Off Half Its Workstaff

McConnell: Targacept downsizing not a concern

Targacept says it will eliminate 65 jobs

Targacept says it will eliminate 65 jobs

Targacept to cut 46% of workers on trial setbacks

Targacept (TRGT) to Reduce Workforce by 65; Clinical Development SVP Dunbar to Retire

Targacept announces 46% reduction in workforce

Targacept Announces Reduction in Force and Plan to Focus Resources on Later-Stage Pipeline

Targacept to Report First Quarter 2012 Financial Results on May 3, 2012

Targacept to Report First Quarter 2012 Financial Results on May 3, 2012

Targacept (TRGT) Can Fail and Yet Still Win for Investors - Barron's

Key Biotech Issues To Watch (XBI, ANIK, BCRX, CBST, DNDN, GILD, ILMN, TRGT)

Targacept is compelling at these levels for long-term investors, Barron's says

Hedge Fund Giant Seth Klarman Gives Up Targacept; Sold Out

Targacept: Drug missed goal due to analysis error

Targacept reports error in asthma study

Baupost unloads Targacept, FMR buys up

Targacept falls in pre-market, breaks range lows, support at $4.17

FMR LLC Raises Stake in Targacept, Inc. (TRGT) to 11.63%

Targacept (TRGT) Reports ID Error in Revised Top-Line Results from TC-6987 Phase 2

Targacept falls 17.4%

Targacept reports on reanalysis of Phase 2 clinical study of TC-6987

Targacept Announces Revised Top-Line Results from Exploratory Phase 2 Study of TC-6987 in Asthma

Big investor sells out of Targacept

Targacept's neuro modulator works in exploratory asthma trial, but not in diabetes

MDD Drug Dropped by AstraZeneca, Targacept After Phase III Failures

Targacept Gets Mixed Results on Drug Trials (TRGT, AZN)

Targacept drug does well against asthma, fails in diabetes

See More Articles...